Compare STRA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | AGIO |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1996 | 2013 |
| Metric | STRA | AGIO |
|---|---|---|
| Price | $80.32 | $28.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $96.50 | $37.63 |
| AVG Volume (30 Days) | 302.2K | ★ 662.0K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 5.41 | N/A |
| Revenue | ★ $997,137,000.00 | $43,011,000.00 |
| Revenue This Year | $4.71 | $75.68 |
| Revenue Next Year | $2.48 | $167.63 |
| P/E Ratio | $14.85 | ★ N/A |
| Revenue Growth | ★ 57.23 | N/A |
| 52 Week Low | $72.17 | $22.24 |
| 52 Week High | $92.98 | $46.00 |
| Indicator | STRA | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.00 | 48.10 |
| Support Level | $79.98 | $26.48 |
| Resistance Level | $84.71 | $29.49 |
| Average True Range (ATR) | 3.18 | 1.10 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 35.02 | 35.30 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.